Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy.

Corso, A; Mangiacavalli, S; Barbarano, L; Montalbetti, L; Mazzone, A; Fava, S; Varettoni, M; Zappasodi, P; Morra, E; Lazzarino, M

Corso, A; Mangiacavalli, S; Barbarano, L; Montalbetti, L; Mazzone, A; Fava, S; Varettoni, M; Zappasodi, P; Morra, E; Lazzarino, M.

Affiliation

Corso A; Division of Hematology, IRRCS Fondazione Policlinico San Matteo, University of Pavia, Via Golgi 2, 27100 Pavia, Italy. a.corso@smatteo.pv.it

Leuk Res ; 32(7): 1085-90, 2008 Jul.

Article in En | MEDLINE | ID: mdl-18096226

Subject(s)

Antineoplastic Agents/therapeutic use; Multiple Myeloma/drug therapy; Thalidomide/therapeutic use; Adult; Aged; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Treatment Outcome

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Thalidomide / Multiple Myeloma / Antineoplastic Agents Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Leuk Res Year: 2008 Document type: Article Affiliation country: Italy Country of publication: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links